Lipase

Lipase levels rise rapidly and significantly when the pancreas is inflamed, damaged, or blocked, making it a key diagnostic marker for acute pancreatitis, chronic pancreatic disease, or pancreatic duct obstruction. Early detection through lipase monitoring enables timely interventions such as managing alcohol intake, addressing gallstones, controlling triglycerides, and adjusting medications that may affect pancreatic health, potentially preventing serious complications.

Most adults benefit from yearly lipase screening alongside the rest of a comprehensive panel. Outside the annual check, retesting is driven by clinical context such as investigating abdominal pain, starting a medication that can affect the pancreas, or monitoring a known condition.

At baseline / for screening: Once every 12 months from age 30 as part of a comprehensive panel. More frequently, every 3 to 6 months, if you have known liver disease, regular alcohol intake, fatty liver (MASLD), or take hepatotoxic medication.

When monitoring an intervention or change: Retesting is driven by clinical context, such as investigating abdominal pain, starting a medication that can affect the pancreas (GLP-1 agonists, valproate, certain antibiotics), or monitoring a known pancreatic condition.

Note: After starting GLP-1 receptor agonists, lipase can rise modestly without true pancreatitis. Retest at 4 to 6 weeks and compare to baseline; otherwise, retesting follows clinical symptoms rather than a fixed cadence.